Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Selumetinib, a highly specific mitogen-activated protein kinase 1/2 inhibitor, is approved for children older than 2 years of age with neurofibromatosis 1 who have inoperable plexiform neurofibromas. By selectively binding to mitogen-activated protein kinase 1/2 proteins, selumetinib can arrest the mitogen-activated protein kinase/extracellular sig...
Alternative Titles
Full title
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7935771
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7935771
Other Identifiers
ISSN
0312-5963,1179-1926
E-ISSN
1179-1926
DOI
10.1007/s40262-020-00967-y
